Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Heparanase (HPSE) is the dominant mammalian endoglycosidase and important tumorigenic, angiogenic, and pro-metastatic molecule. Highest levels of HPSE activity have been consistently detected in cells possessing highest propensities to colonize the brain, emphasizing the therapeutic potential for t...

Full description

Bibliographic Details
Main Authors:	Lixin Zhang, Jason A. Ngo, Michael D. Wetzel, Dario Marchetti
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558614001882

Similar Items

Role of Heparanase and Heparanase-Degraded Heparan Sulfate in Brain-metastatic Melanoma
by: Roy, Madhuchhanda
Published: (2007)

Targeted treatment of advanced and metastatic breast cancer with lapatinib
by: Brendan Corkery, et al.
Published: (2008-09-01)

FGF2 Binding, Signaling, Angiogenesis Are Modulated by Heparanase in Metastatic Melanoma Cells
by: Jane Reiland, et al.
Published: (2006-07-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
by: Catherine Oakman, et al.
Published: (2010-01-01)

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
by: Geneviève Deblois, et al.
Published: (2016-07-01)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
by: Sofia Agelaki, et al.
Published: (2015-01-01)

The Role of Heparanase in Malignant Melanoma and the Development of a Brain Slice Model to Study Mechanisms of Brain Metastatic Melanoma in Vivo
by: Murry, Brian Paul
Published: (2005)

Antisense-Mediated Suppression of Heparanase Gene Inhibits Melanoma Cell Invasion
by: Madhuchhanda Roy, et al.
Published: (2005-03-01)

Association between efficacy and skin rash following treatment with the lapatinib in metastatic breast cancer
by: Suleyman Temiz, et al.
Published: (2016-04-01)

Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01)

Response and resistance to lapatinib in HER2-overexpressing breast cancer
by: Leung, Wing Yin
Published: (2014)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
by: Yizhao Xie, et al.
Published: (2020-05-01)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
by: Erica M. Stringer-Reasor, et al.
Published: (2021-03-01)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
by: A. Geneste, et al.
Published: (2020-08-01)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
by: Shengnan Bao, et al.
Published: (2020-09-01)

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
by: John D. Strickley, et al.
Published: (2018-08-01)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
by: Min Ye, et al.
Published: (2021-07-01)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
by: Punam Rana, et al.
Published: (2012-01-01)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
by: Punam Rana, et al.
Published: (2012-03-01)

Lapatinib for HER2 overexpressing breast cancer
by: Jones, Jeremy, et al.
Published: (2009)

Role of yes-associated protein in resistance of HER2+ breast cancer to lapatinib
by: CHEN Peng, et al.
Published: (2020-04-01)

The role of NF-kB activation in lapatinib resistant in breast cancer cells
by: Meng-Chieh Yu, et al.
Published: (2012)

HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy
by: Chiara Saggia
Published: (2018-06-01)

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
by: Azeem Saleem, et al.
Published: (2017-09-01)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
by: J. Robert McCorkle, et al.
Published: (2021-01-01)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
by: J Robert McCorkle, et al.
Published: (2021-01-01)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
by: Sharad Verma, et al.
Published: (2018-01-01)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
by: Stefania Gori, et al.
Published: (2016-01-01)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021-08-01)

Heparan Sulfate and Heparanase as Modulators of Breast Cancer Progression
by: Angélica M. Gomes, et al.
Published: (2013-01-01)

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
by: Jun Wang, et al.
Published: (2020-01-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Lapatinib for the treatment of HER2-overexpressing breast cancer
by: J Jones, et al.
Published: (2009-10-01)

High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
by: A P Seryakov, et al.
Published: (2014-06-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
by: Ro Jungsil, et al.
Published: (2012-07-01)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
by: Trevor Dennie
Published: (2015-01-01)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
by: Hye Jin Lee, et al.
Published: (2020-09-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
by: Raffaele Ardito, et al.
Published: (2018-09-01)